Wafaa S El-Sherbeny1, Nesreen M Sabry2, Radwa M Sharbay3. 1. Cardiovascular Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Wfelsherbeny@gmail.com. 2. Clinical Oncology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. 3. Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Abstract
BACKGROUND: Adjuvant trastuzumab improved overall survival and reduced the risk for disease recurrence in women with breast cancers, because of its potential cardiotoxicity, careful monitoring of left ventricular (LV) function during treatment is required. METHODS: This study investigates, whether myocardial strain imaging and level of N-terminal pro-brain natriuretic peptide (NT-pro BNP) could predict subsequent reduction in LVEF in breast cancer patients received adjuvant trastuzumab. 61 women with pathologically proven breast cancer HER-2 positive received AC (Doxorubicin-Cyclophosphamide) for 4 cycles, followed by paclitaxel with Trastuzumab were enrolled. Clinical, conventional echocardiographic parameters, myocardial strain imaging [global longitudinal peak systolic strain (GLS), radial and circumferential systolic strain] and level of NT pro-BNP were measured at baseline, after 3, 6, 9 and 12 months of trastuzumab therapy. RESULTS: Of 61 patients, 18 patients (29.5%) developed trastuzumab-induced cardiomyopathy (CM) at 6 and 9 months of therapy (LVEF declines ≥ 10%), GLS and radial strain significantly decreased in CM group at 3 months of trastuzumab treatment, the value of GLS at 3 months was the strongest predictors of cardiotoxicity its area under the curve (AUC 0.98) with an optimal cut-off for GLS (- 18%) having 92.5% sensitivity and 83% specificity. NT-pro BNP levels were not predictive of later trastuzumab-induced cardiac dysfunction. CONCLUSION: Myocardial strain imaging has been able to predict pre-clinical changes in LV systolic function and GLS is an independent early predictor of subsequent reduction in EF in breast cancer patients treated with trastuzumab.
BACKGROUND: Adjuvant trastuzumab improved overall survival and reduced the risk for disease recurrence in women with breast cancers, because of its potential cardiotoxicity, careful monitoring of left ventricular (LV) function during treatment is required. METHODS: This study investigates, whether myocardial strain imaging and level of N-terminal pro-brain natriuretic peptide (NT-pro BNP) could predict subsequent reduction in LVEF in breast cancerpatients received adjuvant trastuzumab. 61 women with pathologically proven breast cancerHER-2 positive received AC (Doxorubicin-Cyclophosphamide) for 4 cycles, followed by paclitaxel with Trastuzumab were enrolled. Clinical, conventional echocardiographic parameters, myocardial strain imaging [global longitudinal peak systolic strain (GLS), radial and circumferential systolic strain] and level of NT pro-BNP were measured at baseline, after 3, 6, 9 and 12 months of trastuzumab therapy. RESULTS: Of 61 patients, 18 patients (29.5%) developed trastuzumab-induced cardiomyopathy (CM) at 6 and 9 months of therapy (LVEF declines ≥ 10%), GLS and radial strain significantly decreased in CM group at 3 months of trastuzumab treatment, the value of GLS at 3 months was the strongest predictors of cardiotoxicity its area under the curve (AUC 0.98) with an optimal cut-off for GLS (- 18%) having 92.5% sensitivity and 83% specificity. NT-pro BNP levels were not predictive of later trastuzumab-induced cardiac dysfunction. CONCLUSION: Myocardial strain imaging has been able to predict pre-clinical changes in LV systolic function and GLS is an independent early predictor of subsequent reduction in EF in breast cancerpatients treated with trastuzumab.
Entities:
Keywords:
Breast cancer; Cardiotoxicity; Myocardial strain; Trastuzumab
Authors: Emily Ho; Angela Brown; Patrick Barrett; Roisin B Morgan; Gerard King; M John Kennedy; Ross T Murphy Journal: Heart Date: 2010-05 Impact factor: 5.994
Authors: Suchi Grover; Darryl P Leong; Adhiraj Chakrabarty; Lucas Joerg; Dusan Kotasek; Kerry Cheong; Rohit Joshi; Majo X Joseph; Carmine DePasquale; Bogda Koczwara; Joseph B Selvanayagam Journal: Int J Cardiol Date: 2013-08-02 Impact factor: 4.164
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Timothy C Tan; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Circ Cardiovasc Imaging Date: 2012-06-28 Impact factor: 7.792
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Am J Cardiol Date: 2011-03-02 Impact factor: 2.778
Authors: Bonnie Ky; Mary Putt; Heloisa Sawaya; Benjamin French; James L Januzzi; Igal A Sebag; Juan Carlos Plana; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: J Am Coll Cardiol Date: 2013-11-27 Impact factor: 24.094
Authors: Edith A Perez; Vera J Suman; Nancy E Davidson; George W Sledge; Peter A Kaufman; Clifford A Hudis; Silvana Martino; Julie R Gralow; Shaker R Dakhil; James N Ingle; Eric P Winer; Karen A Gelmon; Bernard J Gersh; Allan S Jaffe; Richard J Rodeheffer Journal: J Clin Oncol Date: 2008-02-04 Impact factor: 44.544
Authors: J R Mackey; M Clemons; M A Côté; D Delgado; S Dent; A Paterson; L Provencher; M B Sawyer; S Verma Journal: Curr Oncol Date: 2008-01 Impact factor: 3.677
Authors: Gabriel Silva Marques Borges; Eduardo Burgarelli Lages; Pierre Sicard; Lucas Antônio Miranda Ferreira; Sylvain Richard Journal: Front Cardiovasc Med Date: 2021-06-30